GTTX Stock Overview
A biopharmaceutical company, focuses on the development of precision gene editing therapies based on its GeneTether platform for human therapeutics applications. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GeneTether Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.10 |
| 52 Week High | CA$0.10 |
| 52 Week Low | CA$0.015 |
| Beta | -1.56 |
| 11 Month Change | 300.00% |
| 3 Month Change | n/a |
| 1 Year Change | 566.67% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| GTTX | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 400.0% | -8.5% | 0.7% |
| 1Y | 566.7% | 1.5% | 21.7% |
Return vs Industry: GTTX exceeded the Canadian Biotechs industry which returned -0.4% over the past year.
Return vs Market: GTTX exceeded the Canadian Market which returned 21.4% over the past year.
Price Volatility
| GTTX volatility | |
|---|---|
| GTTX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: GTTX's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: Insufficient data to determine GTTX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Roland Boivin | genetether.com |
GeneTether Therapeutics Inc., a biopharmaceutical company, focuses on the development of precision gene editing therapies based on its GeneTether platform for human therapeutics applications. It is developing gene therapies for the treatment of patients with rare and monogenic kidney and skin diseases. The company was founded in 2018 and is based in Kelowna, Canada.
GeneTether Therapeutics Inc. Fundamentals Summary
| GTTX fundamental statistics | |
|---|---|
| Market cap | CA$3.87m |
| Earnings (TTM) | -CA$831.84k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.7x
P/E RatioIs GTTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GTTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$595.81k |
| Earnings | -US$595.81k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.015 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GTTX perform over the long term?
See historical performance and comparison